BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Business Insider17 小时
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel ...
BioNTech to Acquire Biotheus for $800 Million to Expand Oncology Portfolio
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...
阿思達克財經網2 天
高盛上调BioNTech(BNTX.US)评级 指新癌症治疗方法利好
高盛上调德国生技公司BioNTech(BNTX.US)评级，由「中性」上调至「买入」，并将目标价从90美元上调至137美元，意味着较周四收市 ...
Seeking Alpha on MSN22 小时
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
BioNTech股票因新癌症药物潜力获得上调评级
周五，高盛修改了对BioNTech (NASDAQ:BNTX)的立场，将该股票从中性上调至买入。该投资公司还将这家生物技术公司的目标价从之前的90.00美元上调至137.00美元。这一调整反映了该公司对BioNTech正在临床开发的BNT327的乐观态度，这是一种针对多种实体瘤适应症的创新免疫肿瘤学资产。 围绕BioNTech股票的乐观情绪源于BNT327的潜力，这是一种正在进行临床试验的PDL1 ...
BioNTech SE (BNTX) Gets a Buy from Morgan Stanley
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
BMO将BioNTech目标价上调至126美元，原因是收入强劲
周一，BMO Capital Markets维持对BioNTech SE (NASDAQ:BNTX)的"优于大市"评级，并将目标价从122美元上调至126美元。这一修订是在BioNTech报告季度收入为12.4亿欧元，超过FactSet共识142%之后做出的。尽管公司预计2024财年收入将处于25-31亿欧元预测区间的下限，但仍确认了这一指引。 BioNTech最近的财务披露还显示，虽然研发（R& ...
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.